Comparison of molecular testing methods for the detection of <i>EGFR</i> mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer

Abstract

The invalid rates for the cobas test and Therascreen were lower than Sanger sequencing. The cobas and Therascreen assays showed a high degree of concordance, and both were more sensitive for the detection of exon 19 deletion and L858R mutations than Sanger. The cobas test was highly reproducible between the two testing sites, used the least amount of DNA input and was the only test with automated results reporting.